IL17D and breast carcinoma: Furthermore, out of the 150 potential markers identified in this study, a few proteins Defensin (DEFA4), α-2-macroglobulin receptor-associated protein (LRPAP1), Interleukin-18-binding protein (IL18BP), Interleukin-17D (IL17D) and ER degradation-enhancing α-mannosidase-like protein 2 (EDEM2) are not currently linked specifically to breast cancer and may therefore represent completely new markers of breast cancer potentially suitable for population screening applications.